Prasterone
- Generic Name
- Prasterone
- Brand Names
- Intrarosa
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O2
- CAS Number
- 53-43-0
- Unique Ingredient Identifier
- 459AG36T1B
- Background
Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion....
- Indication
DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease ...
- Associated Conditions
- Moderate Dyspareunia, Severe Dyspareunia
- Associated Therapies
- -
Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans
- Conditions
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 56
- Registration Number
- NCT00099697
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Dehydroepiandrosterone Effects on HIV-1 Replication
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2006-08-18
- Target Recruit Count
- 40
- Registration Number
- NCT00065104
- Locations
- 🇺🇸
Community Consortium, San Francisco, California, United States
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00006219
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 190
- Registration Number
- NCT00004795
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 300
- Registration Number
- NCT00004662
Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 20
- Registration Number
- NCT00004665
Treatment of Mid-Life-Related Mood Disorders
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 60
- Registration Number
- NCT00001487
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
DHEA Treatment for Sjogren's Syndrome
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 28
- Registration Number
- NCT00001598
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 40
- Registration Number
- NCT00004313
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.